Bruce Freundlich

4.8k total citations · 1 hit paper
54 papers, 3.8k citations indexed

About

Bruce Freundlich is a scholar working on Rheumatology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Bruce Freundlich has authored 54 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Rheumatology, 18 papers in Pathology and Forensic Medicine and 16 papers in Immunology. Recurrent topics in Bruce Freundlich's work include Rheumatoid Arthritis Research and Therapies (20 papers), Autoimmune and Inflammatory Disorders Research (10 papers) and Systemic Lupus Erythematosus Research (10 papers). Bruce Freundlich is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (20 papers), Autoimmune and Inflammatory Disorders Research (10 papers) and Systemic Lupus Erythematosus Research (10 papers). Bruce Freundlich collaborates with scholars based in United States, Germany and United Kingdom. Bruce Freundlich's co-authors include Joel Rosenbloom, Nebojša Avdalović, Andrew Koenig, Ronald Pedersen, Sergio A. Jiménez, Deborah Robertson, Jack A. Elias, Paul Emery, Ferdinand C. Breedveld and Amitabh Singh and has published in prestigious journals such as The Lancet, Annals of Internal Medicine and American Journal of Epidemiology.

In The Last Decade

Bruce Freundlich

54 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

2008 652 citations Paul Emery, Ferdinand C. Breedveld et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bruce Freundlich United States	34	2.0k	1.2k	795	583	413	54	3.8k
Giovanni Lapadula Italy	38	2.1k 1.1×	1.0k 0.8×	628 0.8×	576 1.0×	355 0.9×	191	4.5k
G Pasero Italy	29	2.7k 1.4×	1.1k 0.9×	777 1.0×	780 1.3×	269 0.7×	117	4.9k
Francesco Trotta Italy	36	1.9k 1.0×	891 0.7×	516 0.6×	523 0.9×	343 0.8×	154	3.6k
Erika Gromnica‐Ihle Germany	32	2.9k 1.5×	1.0k 0.8×	989 1.2×	422 0.7×	860 2.1×	87	4.7k
Luis J. Jara Mexico	37	2.0k 1.0×	1.2k 1.0×	361 0.5×	515 0.9×	316 0.8×	122	3.7k
Ori Elkayam Israel	39	2.1k 1.1×	1.6k 1.3×	840 1.1×	319 0.5×	436 1.1×	155	4.5k
Éric Toussirot France	44	2.4k 1.2×	1.5k 1.2×	667 0.8×	499 0.9×	426 1.0×	223	5.2k
Christophe Richez France	37	2.4k 1.2×	2.2k 1.8×	560 0.7×	551 0.9×	298 0.7×	148	4.6k
Jozélio Freire de Carvalho Brazil	35	2.0k 1.0×	1.0k 0.8×	557 0.7×	571 1.0×	521 1.3×	275	4.3k
Terry L. Moore United States	31	1.2k 0.6×	887 0.7×	882 1.1×	351 0.6×	179 0.4×	141	3.2k

Countries citing papers authored by Bruce Freundlich

Since Specialization

Citations

This map shows the geographic impact of Bruce Freundlich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce Freundlich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce Freundlich more than expected).

Fields of papers citing papers by Bruce Freundlich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce Freundlich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce Freundlich. The network helps show where Bruce Freundlich may publish in the future.

Co-authorship network of co-authors of Bruce Freundlich

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce Freundlich. A scholar is included among the top collaborators of Bruce Freundlich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce Freundlich. Bruce Freundlich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schiff, Michael, Jonathan S. Jaffe, & Bruce Freundlich. (2014). Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Annals of the Rheumatic Diseases. 73(8). 1549–1551. 123 indexed citations

Song, In‐Ho, Christian E. Althoff, Hildrun Haibel, et al.. (2012). Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Annals of the Rheumatic Diseases. 71(7). 1212–1215. 68 indexed citations

Emery, Paul, Tore K Kvien, Bernard Combe, et al.. (2012). Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Annals of the Rheumatic Diseases. 71(6). 989–992. 62 indexed citations

Althoff, Christian E., Joachim Sieper, In‐Ho Song, et al.. (2012). Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI. Annals of the Rheumatic Diseases. 72(6). 967–973. 111 indexed citations

Haraoui, Boulos, P. L. C. M. van Riel, Jörn Kekow, et al.. (2011). Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.. PubMed. 29(1). 26–34. 48 indexed citations

Koike, Takao, Masayoshi Harigai, Shigeko Inokuma, et al.. (2011). Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Modern Rheumatology. 21(4). 343–351. 77 indexed citations

Emery, Paul, Ferdinand C. Breedveld, Désirée van der Heijde, et al.. (2010). Two‐year clinical and radiographic results with combination etanercept–methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two‐year, double‐blind, randomized study. Arthritis & Rheumatism. 62(3). 674–682. 96 indexed citations

Koike, Takao, Masayoshi Harigai, Shigeko Inokuma, et al.. (2009). Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan. The Journal of Rheumatology. 36(5). 898–906. 141 indexed citations

Keystone, Edward, Bruce Freundlich, Michael Schiff, Juan Li, & Michele Hooper. (2009). Patients with Moderate Rheumatoid Arthritis (RA) Achieve Better Disease Activity States with Etanercept Treatment Than Patients with Severe RA. The Journal of Rheumatology. 36(3). 522–531. 24 indexed citations

10.

Emery, Paul, Patrick Durez, Ferdinand C. Breedveld, et al.. (2007). Remission rates in subjects with active early rheumatoid arthritis 1 year results of the COMET trial: Combination of methotrexate and etanercept in active early rheumatoid arthritis. DIAL (Catholic University of Leuven). 56(12). 4310–4311. 5 indexed citations

11.

Gelfand, Joel M., Alexa B. Kimball, Eliot N. Mostow, et al.. (2007). Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept: Continuous versus Interrupted Treatment. Value in Health. 11(3). 400–407. 51 indexed citations

12.

Juhász, István, et al.. (1996). Transplantation of Systemic Sclerosis (SSc) Skin Grafts into Severe Combined Immunodef icient Mice: Increased Presence of SSc Leukocytes in SSc Skin Grafts and Autoantibody Production following Autologous Leukocyte Transfer. Pathobiology. 64(2). 99–114. 6 indexed citations

13.

Leventhal, Lawrence J., et al.. (1995). Controlled Study of Sleep Parameters in Patients with Fibromyalgia. JCR Journal of Clinical Rheumatology. 1(2). 110–113. 14 indexed citations

14.

Glosser, Guila, et al.. (1995). A controlled investigation of current and premorbid personality: Characteristics of Parkinson's disease patients. Movement Disorders. 10(2). 201–206. 70 indexed citations

15.

West, Suzanne L., Brian L. Strom, Bruce Freundlich, et al.. (1994). Completeness of prescription recording in outpatient medical records from a health maintenance organization. Journal of Clinical Epidemiology. 47(2). 165–171. 68 indexed citations

16.

Schumacher, Henrik, et al.. (1993). Pulmonary alveolar hemorrhage in systemic lupus erythematosus. Seminars in Arthritis and Rheumatism. 23(1). 8–15. 106 indexed citations

17.

Freundlich, Bruce, et al.. (1992). Treatment of systemic sclerosis with recombinant interferon‐γ. A phase I/II clinical trial. Arthritis & Rheumatism. 35(10). 1134–1142. 58 indexed citations

18.

Elias, Jack A., Bruce Freundlich, Sherrill Adams, & Joel Rosenbloom. (1990). Regulation of Human Lung Fibroblast Collagen Production by Recombinant Interleukin‐1, Tumor Necrosis Factor, and Interferon‐γ^a. Annals of the New York Academy of Sciences. 580(1). 233–244. 69 indexed citations

19.

Freundlich, Bruce, et al.. (1988). A Novel Antinuclear Antibody Associated with a Lupus-like Paraneoplastic Syndrome. Annals of Internal Medicine. 109(4). 295–297. 33 indexed citations

20.

Elias, Jack A., et al.. (1988). Human Alveolar Macrophage and Blood Monocyte Inhibition of Fibroblast Proliferation: Evidence for Synergy between Interleukin-1 and Tumor Necrosis Factor. American Review of Respiratory Disease. 138(6). 1595–1603. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact